Advances In™ Follicular Lymphoma: Highlighting the Latest Practice Changing-Evidence in Treatment

Release Date: November 15, 2021
Expiration Date: November 15, 2022

Activity Overview

Acknowledgement of Commercial Support

This activity is supported by educational grants from Epizyme, Inc., and Genentech.
 

Target Audience

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Discuss evolving understanding of the pathogenesis and mechanistic rationale underlying the application of novel strategies for FL management.
• Evaluate safety and efficacy profiles of current and emerging agents/combinations for patients with FL.
• Assess the impact of emerging data as well as strategies in the context of evolving treatment paradigms in the management of patients with FL.
• Identify patients with FL who may benefit from clinical trial participation evaluating emerging therapies and/or strategies.

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
 

Faculty

Catherine S. M. Diefenbach, MD
Associate Professor of Medicine, Clinical Director of Lymphoma, Translational Director of Hematology
Perlmutter Cancer Center at NYU Langone Health
New York, NY
 

Disclosures: Consultant: Roche/Genentech, Merck & Co., Bristol Myers Squibb, Seattle Genetics, MorphoSys; Stock/Shareholder: Gilead Sciences.
 

Gilles Salles, MD, PhD
Chief, Lymphoma Service
Memorial Sloan Kettering Cancer Center
New York, NY
 

Disclosures: Consultant: AbbVie, Bayer HealthCare Pharmaceuticals, BeiGene, Bristol Myers Squibb/Celgene, Debiopharm, Epizyme, Genentech/Roche Genmab, Incyte, Ipsen, Janssen Pharmaceuticals, Kite/Gilead, Loxo Oncology, Miltenyi Biotech, MorphoSys, Novartis, Rapt Therapeutics, Regeneron, Takeda Pharmaceutical, VelosBio.

PER^® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.